Cargando…

Vulvar leukoplakia: therapeutic options

Vulvar leukoplakia is not a histological diagnosis and involves several diseases. Most commonly, these are vulvar lichen sclerosus and squamous cell hyperplasia of the vulva. These two conditions have similar aetiology, clinical presentation and treatment but different histopathological changes. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Yordanov, Angel, Tantchev, Latchezar, Kostov, Stoyan, Slavchev, Stanislav, Strashilov, Strahil, Vasileva, Polina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573333/
https://www.ncbi.nlm.nih.gov/pubmed/33100949
http://dx.doi.org/10.5114/pm.2020.99570
_version_ 1783597419381915648
author Yordanov, Angel
Tantchev, Latchezar
Kostov, Stoyan
Slavchev, Stanislav
Strashilov, Strahil
Vasileva, Polina
author_facet Yordanov, Angel
Tantchev, Latchezar
Kostov, Stoyan
Slavchev, Stanislav
Strashilov, Strahil
Vasileva, Polina
author_sort Yordanov, Angel
collection PubMed
description Vulvar leukoplakia is not a histological diagnosis and involves several diseases. Most commonly, these are vulvar lichen sclerosus and squamous cell hyperplasia of the vulva. These two conditions have similar aetiology, clinical presentation and treatment but different histopathological changes. They both lead to significant impairment of quality of life, risk of malignancy, as well as recurrence after treatment. Treatment of these conditions includes topical corticosteroids as a first-line therapy, but they have their side effects and not all patients are receptive to this therapy. This requires the use of alternative therapeutic options such as topical calcineurin inhibitors, topical and systemic retinoids, other steroid creams, various destructive techniques and, as a last resort, surgical removal of affected tissues. Surgical treatment should be avoided, despite the malignant potential, because of recurrence risk in both diseases New therapeutic approaches are coming into effect in gynaecological practice due to potential risks of the above-mentioned methods. Platelet-rich plasma therapy, ablative and non-ablative laser treatment, and new topical medicines, are some of the new options applied to improve the efficacy of treatment avoiding the side effects of conventional medications. A number of them are still in their initial phase of application and time will tell their effectiveness.
format Online
Article
Text
id pubmed-7573333
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Termedia Publishing House
record_format MEDLINE/PubMed
spelling pubmed-75733332020-10-23 Vulvar leukoplakia: therapeutic options Yordanov, Angel Tantchev, Latchezar Kostov, Stoyan Slavchev, Stanislav Strashilov, Strahil Vasileva, Polina Prz Menopauzalny Review Paper Vulvar leukoplakia is not a histological diagnosis and involves several diseases. Most commonly, these are vulvar lichen sclerosus and squamous cell hyperplasia of the vulva. These two conditions have similar aetiology, clinical presentation and treatment but different histopathological changes. They both lead to significant impairment of quality of life, risk of malignancy, as well as recurrence after treatment. Treatment of these conditions includes topical corticosteroids as a first-line therapy, but they have their side effects and not all patients are receptive to this therapy. This requires the use of alternative therapeutic options such as topical calcineurin inhibitors, topical and systemic retinoids, other steroid creams, various destructive techniques and, as a last resort, surgical removal of affected tissues. Surgical treatment should be avoided, despite the malignant potential, because of recurrence risk in both diseases New therapeutic approaches are coming into effect in gynaecological practice due to potential risks of the above-mentioned methods. Platelet-rich plasma therapy, ablative and non-ablative laser treatment, and new topical medicines, are some of the new options applied to improve the efficacy of treatment avoiding the side effects of conventional medications. A number of them are still in their initial phase of application and time will tell their effectiveness. Termedia Publishing House 2020-10-02 2020-09 /pmc/articles/PMC7573333/ /pubmed/33100949 http://dx.doi.org/10.5114/pm.2020.99570 Text en Copyright © 2020 Termedia http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Review Paper
Yordanov, Angel
Tantchev, Latchezar
Kostov, Stoyan
Slavchev, Stanislav
Strashilov, Strahil
Vasileva, Polina
Vulvar leukoplakia: therapeutic options
title Vulvar leukoplakia: therapeutic options
title_full Vulvar leukoplakia: therapeutic options
title_fullStr Vulvar leukoplakia: therapeutic options
title_full_unstemmed Vulvar leukoplakia: therapeutic options
title_short Vulvar leukoplakia: therapeutic options
title_sort vulvar leukoplakia: therapeutic options
topic Review Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573333/
https://www.ncbi.nlm.nih.gov/pubmed/33100949
http://dx.doi.org/10.5114/pm.2020.99570
work_keys_str_mv AT yordanovangel vulvarleukoplakiatherapeuticoptions
AT tantchevlatchezar vulvarleukoplakiatherapeuticoptions
AT kostovstoyan vulvarleukoplakiatherapeuticoptions
AT slavchevstanislav vulvarleukoplakiatherapeuticoptions
AT strashilovstrahil vulvarleukoplakiatherapeuticoptions
AT vasilevapolina vulvarleukoplakiatherapeuticoptions